<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2075-082X-2026-1-17-25</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-869</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Клинический портрет и особенности антигипертензивной терапии у коморбидных больных с артериальной гипертонией и сахарным диабетом 2 типа по данным национального регистра АГ</article-title><trans-title-group xml:lang="en"><trans-title>Clinical Profile and Antihypertensive Treatment Patterns in Patients with Comorbid Hypertension and Type 2 Diabetes Mellitus:  Insights from the National Hypertension Registry</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8048-4882</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксенова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksenova</surname><given-names>Anna V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аксенова Анна Владимировна, к.м.н., старший научный сотрудник, отдел гипертонии, </p><p>ул. Академика Чазова, д. 15а, г. Москва, 121552.</p><p>тел.: 8 (495) 414-61-86.</p></bio><bio xml:lang="en"><p>Anna V. Aksenova, Cand. of Sci. (Med.), Senior Researcher, Department of Hypertension,</p><p>acad. Chazova str., 15a, Moscow, 121552.</p><p>Phone: 8 (495) 414-61-86.</p></bio><email xlink:type="simple">aksenovaannav@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0600-8532</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарян</surname><given-names>Р. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarian</surname><given-names>Raia S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макарян Рая Самвеловна, аспирант, отдел гипертонии,</p><p>ул. Академика Чазова, д. 15а, г. Москва, 121552.</p><p>Тел.: 8 (495) 414-67-70.</p></bio><bio xml:lang="en"><p>Raia S. Makarian, Postgraduate Student, Department of Hypertension,</p><p>acad. Chazova str., 15a, Moscow, 121552.</p></bio><email xlink:type="simple">makaryanraya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8543-1326</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Серов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Serov</surname><given-names>Ivan S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Серов Иван Сергеевич, врач-терапевт,</p><p>пр-т Шереметевский, д. 22, г. Иваново, 153012.</p><p>тел.: 8 (493) 234-56-05.</p></bio><bio xml:lang="en"><p>Ivan S. Serov, Therapist, </p><p>22, Sheremetevsky Ave., Ivanovo, 153012.</p></bio><email xlink:type="simple">mrleofitz@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7164-0086</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Belova</surname><given-names>Olga A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белова Ольга Анатольевна, заместитель главного врача по организационно-методической работе,</p><p>пр-т Шереметевский, д. 22, г. Иваново, 153012.</p><p>тел.: 8 (493) 232-67-84.</p></bio><bio xml:lang="en"><p>Olga A. Belova, Deputy Chief Physician for Organizational and Methodological Work, </p><p>22, Sheremetevsky Ave., Ivanovo, 153012.</p></bio><email xlink:type="simple">bel_olga@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0833-8201</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рачкова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rachkova</surname><given-names>Svetlana A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рачкова Светлана Алексеевна, главный врач,</p><p>пр-т Шереметевский, д. 22, г. Иваново, 153012.</p><p>тел.: 8 (493) 232-51-81.</p></bio><bio xml:lang="en"><p>Svetlana A. Rachkova, Chief Physician, </p><p>22, Sheremetevsky Ave., Ivanovo, 153012.</p></bio><email xlink:type="simple">svetlana-dr@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9822-4357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>Irina E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чазова Ирина Евгеньевна, акад. РАН, д.м.н., профессор, заместитель генерального директора, руководитель отдела гипертонии,</p><p>ул. Академика Чазова, д. 15а, г. Москва, 121552.</p></bio><bio xml:lang="en"><p>Irina E. Chazova, Academician of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Deputy Director General, Head of the Hypertension Department,</p><p>acad. Chazova str., 15a, Moscow, 121552.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.I. Chazov National Medical Research Centre of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ОБУЗ «Кардиологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Budgetary Healthcare Institution «Cardiological Dispensary»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>01</day><month>04</month><year>2026</year></pub-date><volume>23</volume><issue>1</issue><fpage>17</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аксенова А.В., Макарян Р.С., Серов И.С., Белова О.А., Рачкова С.А., Чазова И.Е., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Аксенова А.В., Макарян Р.С., Серов И.С., Белова О.А., Рачкова С.А., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Aksenova A.V., Makarian R.S., Serov I.S., Belova O.A., Rachkova S.A., Chazova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/869">https://www.syst-hypertension.ru/jour/article/view/869</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Высокая распространенность сахарного диабета среди пациентов с артериальной гипертонией (АГ) и повышенный риск сердечнососудистых осложнений обуславливает необходимость более тщательного изучения особенностей этой группы пациентов в реальной клинической практике для оптимизации подхода к их ведению.</p></sec><sec><title>Цель</title><p>Цель: выявление клинических особенностей коморбидных пациентов с АГ и сахарным диабетом 2 типа и оценка особенностей проводимой антигипертензивной терапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 57396 пациентов национального регистра АГ, разделенные на 2 группы по принципу наличия или отсутствия сахарного диабета. Проводилась оценка социальных факторов, особенностей анамнеза, модифицируемых факторов риска развития ССЗ и антигипертензивной терапии. Статистическая обработка данных проведена с использованием среды R 4.3.3 (R foundation for Statistical Computing, Вена, Австрия).</p></sec><sec><title>Результаты</title><p>Результаты. Сахарный диабет 2 типа выявлен у 15,3% пациентов с АГ. Группа пациентов с АГ и сахарным диабетом 2 типа была преимущественно представлена женщинами (66,6%), которые чаще всего имели такие факторы риска как ожирение (55,4%) и низкий уровень физической активности (40,3%). Пациенты с АГ и сахарным диабетом 2 типа по сравнению с пациентами с АГ без сахарного диабета 2 типа статистически значимо были более отягощены наличием хронической сердечной недостаточности (64,4% против 46,0%), ишемической болезни сердца (54,9% против 39,0%), хронической болезни почек (35,8% против 28,3%), нарушения мозгового кровообращения в анамнезе (7,0% против 4,1%). Больные с АГ в сочетании с СД 2 типа более резистентны к лечению, чем пациенты с АГ без СД 2 типа. В этой группе выявлено более частое назначение блокаторов рецептора ангиотензина II (24,7% против 16,7%), бета-блокаторов (59,5% против 51,5%), блокаторов кальциевых каналов (22,3% против 15,1%).</p></sec><sec><title>Выводы</title><p>Выводы. Выявленные изменения отражают дополнительное негативное влияние СД 2 типа на течение АГ и развитие ССО. В связи с высокой отягощенностью данной группы пациентов кардиальными и некардиальными патологиями необходим более агрессивный и многокомпонентный подход к терапии. Полученные результаты подчеркивают необходимость разработки комплексных программ профилактики, ранней диагностики, индивидуального подхода к назначению терапии. Сочетание АГ и СД 2 типа в РФ требует междисциплинарного подхода с акцентом на контроль метаболических параметров и раннюю профилактику осложнений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. The high prevalence of diabetes mellitus among patients with hypertension and the increased risk of cardiovascular complications necessitate a more detailed study of the characteristics of this patient group in order to optimize their management approach.</p></sec><sec><title>Objective</title><p>Objective. To identify clinical features of comorbid patients with hypertension and diabetes mellitus, as well as to assess their treatment.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of absence of diabetes mellitus. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R foundation for Statistical Computing, Vienna, Austria).</p></sec><sec><title>Results</title><p>Results. Type 2 diabetes mellitus (T2DM) was detected in 15.3% of patients with hypertension (HTN). The group of patients with HTN and type 2 diabetes mellitus was predominantly represented by women (66.6%), who most often had risk factors such as obesity (55.4%) and low physical activity (40.3%). Compared to hypertensive patients without T2DM, those with hypertension and T2DM had significantly higher rates of chronic heart failure (64.4% vs 46.0%), coronary artery disease (54.9% vs 39.0%), chronic kidney disease (35.8% vs 28.3%), and prior cerebrovascular events (7.0% vs 4.1%). Patients with hypertension combined with T2DM demonstrated greater treatment resistance, with more frequent prescriptions of angiotensin receptor blockers (24.7% vs 16.7%), beta-blockers (59.5% vs 51.5%), and calcium channel blockers (22.3% vs 15.1%).</p></sec><sec><title>Conclusions</title><p>Conclusions. The identified changes reflect an additional negative impact of type 2 diabetes on the course of hypertension and the development of cardiovascular complications. Due to the high burden of cardiac and non-cardiac pathologies in this patient group, a more aggressive and multicomponent approach to therapy is required. The obtained results emphasize the need for the development of comprehensive programs for prevention, early diagnosis, and an individualized approach to prescribing therapy. The combination of hypertension and type 2 diabetes in the Russian federation necessitates an interdisciplinary approach with an emphasis on controlling metabolic parameters and the early prevention of complications.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>регистр АГ</kwd><kwd>артериальная гипертония</kwd><kwd>антигипертензивная терапия</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>инфаркт миокарда</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>бета-блокаторы</kwd><kwd>ингибиторы ангиотензинпревращающего фермента</kwd><kwd>блокаторы рецепторов агиотензина II</kwd><kwd>блокаторы кальциевых каналов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension registry</kwd><kwd>arterial hypertension</kwd><kwd>antihypertensive therapy</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>myocardial infarction</kwd><kwd>chronic heart failure</kwd><kwd>betablockers</kwd><kwd>angiotensin-converting enzyme inhibitors</kwd><kwd>angiotensin receptor blockers</kwd><kwd>calcium channel blockers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. https://doi.org/10.1016/j.jacc.2020.11.010</mixed-citation><mixed-citation xml:lang="en">Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. https://doi.org/10.1016/j.jacc.2020.11.010</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389(10064):37-55. https://doi.org/10.1016/S0140-6736(16)31919-5</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389(10064):37-55. https://doi.org/10.1016/S0140-6736(16)31919-5</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Драпкина О.М., Куценко В.А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3785. https://doi.org/10.15829/1728-8800-2023-3785. EDN: YRUNUX</mixed-citation><mixed-citation xml:lang="en">Balanova Yu.A., Drapkina O.M., Kutsenko V.A. et. al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSERF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.) https://doi.org/10.26442/2075082X.2019.1.190179</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(1S):1-148. https://doi.org/10.14341/DM12802</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Shestakova M.V., Mayorov A.Yu et. al. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) https://doi.org/10.14341/DM12802</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112. https://doi.org/10.14341/DM2004116-17</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-112. (In Russ.) https://doi.org/10.14341/DM2004116-17</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Жернакова Ю.В., Чазова И.Е., Ощепкова Е.В. и др. Распространенность сахарного диабета в популяции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ. Системные гипертензии. 2018;15(1):56-62. https://doi.org/10.26442/2075-082X_15.1.56-62</mixed-citation><mixed-citation xml:lang="en">Zhernakova Yu.V., Chazova I.E., Oshchepkova E.V. et al. The prevalence of diabetes mellitus in population of hypertensive patients according to ESSE RF study results. Systemic Hypertension. 2018;15(1):56-62. (In Russ.) https://doi.org/10.26442/2075-082X_15.1.56-62</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardiocerebrovascular diseases: a cross-sectional study. BMC Public Health. 2021;21(1):1224. Published 2021 Jun 25. https://doi.org/10.1186/s12889-021-11122-y</mixed-citation><mixed-citation xml:lang="en">Wang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardiocerebrovascular diseases: a cross-sectional study. BMC Public Health. 2021;21(1):1224. Published 2021 Jun 25. https://doi.org/10.1186/s12889-021-11122-y</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762. https://doi.org/10.1016/s0140-6736(98)04311-6</mixed-citation><mixed-citation xml:lang="en">Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762. https://doi.org/10.1016/s0140-6736(98)04311-6</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119</mixed-citation><mixed-citation xml:lang="en">Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803-1810. https://doi.org/10.1016/S0140-6736(21)01920-6</mixed-citation><mixed-citation xml:lang="en">Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803-1810. https://doi.org/10.1016/S0140-6736(21)01920-6</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Virani S.S., Alonso A., Aparicio H.J. et al. Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–e743. https://doi.org/10.1161/CIR.0000000000000950</mixed-citation><mixed-citation xml:lang="en">Virani S.S., Alonso A., Aparicio H.J. et al. Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–e743. https://doi.org/10.1161/CIR.0000000000000950</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральная служба государственной статистики (Росстаат). Ожидаемая продолжительность жизни в 2023 году. https://rosstat.gov.ru/storage/mediabank/Demogr_ejegod_2023.pdf</mixed-citation><mixed-citation xml:lang="en">Federal State Statistics Service (Rosstat). Life Expectancy in 2023. (In Russ.)https://rosstat.gov.ru/storage/mediabank/Demogr_ejegod_2023.pdf</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4–13. https://doi.org/10.26442/00403660.2019.10.000364</mixed-citation><mixed-citation xml:lang="en">Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019;91(10):4–13. https://doi.org/10.26442/00403660.2019.10.000364</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">IDF DIABETES ATLAS, 10th edition Dianna J. Magliano, Co-chair, Edward J. Boyko, Co-chair; IDF Diabetes Atlas 10th edition scientific committee. Brussels: International Diabetes Federation; 2021. Publication No.: book_idfatlas10e ISBN-13: 978-2-930229-98-0</mixed-citation><mixed-citation xml:lang="en">IDF DIABETES ATLAS, 10th edition Dianna J. Magliano, Co-chair, Edward J. Boyko, Co-chair; IDF Diabetes Atlas 10th edition scientific committee. Brussels: International Diabetes Federation; 2021. Publication No.: book_idfatlas10e ISBN-13: 978-2-930229-98-0</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4-16. https://doi.org/10.1038/hr.2011.173</mixed-citation><mixed-citation xml:lang="en">Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4-16. https://doi.org/10.1038/hr.2011.173</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова А.В., Ощепкова Е.В., Орловский А.А., Чазова И.Е. Гендерно-возрастные особенности роли курения и сахарного диабета в развитии инфаркта миокарда у больных артериальной гипертонией. Системные гипертензии. 2020;17(4):24-31. https://doi.org/10.26442/2075082X.2020.4.200245</mixed-citation><mixed-citation xml:lang="en">Aksenova A.V., Oshchepkova E.V., Orlovskii A.A., Chazova I.E. Gender-age peculiarities of smoking and diabetes mellitus role in the development of myocardial infarction in patients with arterial hypertension. Systemic Hypertension. 2020;17(4):24-31. (In Russ.) https://doi.org/10.26442/2075082X.2020.4.200245</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S429-S431. https://doi.org/10.2337/dc09-S354</mixed-citation><mixed-citation xml:lang="en">Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S429-S431. https://doi.org/10.2337/dc09-S354</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Brož J, Malinovská J, Nunes MA, et al. Prevalence of diabetes and prediabetes and its risk factors in adults aged 25-64 in the Czech Republic: A cross-sectional study. Diabetes Res Clin Pract. 2020;170:108470. https://doi.org/10.1016/j.diabres.2020.108470</mixed-citation><mixed-citation xml:lang="en">Brož J, Malinovská J, Nunes MA, et al. Prevalence of diabetes and prediabetes and its risk factors in adults aged 25-64 in the Czech Republic: A cross-sectional study. Diabetes Res Clin Pract. 2020;170:108470. https://doi.org/10.1016/j.diabres.2020.108470</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Liu M, Zhang W, Yan Z, Yuan X. Smoking increases the risk of diabetic foot amputation: A meta-analysis. Exp Ther Med. 2018;15(2):1680-1685. https://doi.org/10.3892/etm.2017.5538</mixed-citation><mixed-citation xml:lang="en">Liu M, Zhang W, Yan Z, Yuan X. Smoking increases the risk of diabetic foot amputation: A meta-analysis. Exp Ther Med. 2018;15(2):1680-1685. https://doi.org/10.3892/etm.2017.5538</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang N, Huang F, Zhang X. Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. Oncotarget. 2017;8(54):93209-93218. Published 2017 Oct 4. https://doi.org/10.18632/oncotarget.21478</mixed-citation><mixed-citation xml:lang="en">Jiang N, Huang F, Zhang X. Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. Oncotarget. 2017;8(54):93209-93218. Published 2017 Oct 4. https://doi.org/10.18632/oncotarget.21478</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Barengo NC, Teuschl Y, Moltchanov V, Laatikainen T, Jousilahti P, Tuomilehto J. Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland. Tob Induc Dis. 2017;15:12. Published 2017 Feb 2. https://doi.org/10.1186/s12971-017-0113-3</mixed-citation><mixed-citation xml:lang="en">Barengo NC, Teuschl Y, Moltchanov V, Laatikainen T, Jousilahti P, Tuomilehto J. Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland. Tob Induc Dis. 2017;15:12. Published 2017 Feb 2. https://doi.org/10.1186/s12971-017-0113-3</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. Published 2018 Nov 7. https://doi.org/10.1136/bmj.k4247</mixed-citation><mixed-citation xml:lang="en">Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. Published 2018 Nov 7. https://doi.org/10.1136/bmj.k4247</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fox CS, Larson MG, Leip EP, et al. Diabetes and the Risk of Stroke: The Framingham Study. Circulation. 2002;106 (Suppl II):II-818.</mixed-citation><mixed-citation xml:lang="en">Fox CS, Larson MG, Leip EP, et al. Diabetes and the Risk of Stroke: The Framingham Study. Circulation. 2002;106 (Suppl II):II-818.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962 Jul-Aug;21(4)Pt 2:52-7. PMID: 14453051.</mixed-citation><mixed-citation xml:lang="en">Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962 Jul-Aug;21(4)Pt 2:52-7. PMID: 14453051.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877-890.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877-890.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова А.В., Елфимова Е.М., Галицин П.В., Гориева Ш.Б., Бугаев Т.Д., Михайлова О.О., Литвин А.Ю., Рогоза А.Н., Чазова И.Е. Значение компьютерной пульсоксиметрии в практике врача-кардиолога. Системные гипертензии. 2014;11(4):26-30.</mixed-citation><mixed-citation xml:lang="en">Aksenova A.V., Yelfimova Ye.M., Galitsin P.V., Goriyeva Sh.B., Bugayev T.D., Mikhailova O.O., Litvin A.Yu., Rogoza A.N., Chazova I.Ye. Role of the Pulse Oximetry in the cardiologist's practice. Systemic Hypertension. 2014;11(4):26-30. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Esmaeili N, Gell L, Imler T, et al. The relationship between obesity and obstructive sleep apnea in four community-based cohorts: an individual participant data meta-analysis of 12,860 adults. EClinicalMedicine. 2025;83:103221. Published 2025 Apr 23. https://doi.org/10.1016/j.eclinm.2025.103221</mixed-citation><mixed-citation xml:lang="en">Esmaeili N, Gell L, Imler T, et al. The relationship between obesity and obstructive sleep apnea in four community-based cohorts: an individual participant data meta-analysis of 12,860 adults. EClinicalMedicine. 2025;83:103221. Published 2025 Apr 23. https://doi.org/10.1016/j.eclinm.2025.103221</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lecube A, Simó R, Pallayova M, et al. Pulmonary Function and Sleep Breathing: Two New Targets for Type 2 Diabetes Care. Endocr Rev. 2017;38(6):550-573. https://doi.org/10.1210/er.2017-00173</mixed-citation><mixed-citation xml:lang="en">Lecube A, Simó R, Pallayova M, et al. Pulmonary Function and Sleep Breathing: Two New Targets for Type 2 Diabetes Care. Endocr Rev. 2017;38(6):550-573. https://doi.org/10.1210/er.2017-00173</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">A Tahrani A. Obstructive Sleep Apnoea and Vascular Disease in Patients with Type 2 Diabetes. Eur Endocrinol. 2015;11(2):81-89. https://doi.org/10.17925/EE.2015.11.02.81</mixed-citation><mixed-citation xml:lang="en">A Tahrani A. Obstructive Sleep Apnoea and Vascular Disease in Patients with Type 2 Diabetes. Eur Endocrinol. 2015;11(2):81-89. https://doi.org/10.17925/EE.2015.11.02.81</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Collier A, Stirling A, Cameron L, Hair M, Crosbie D. Gout and diabetes: a common combination. Postgrad Med J. 2016;92(1089):372-378. https://doi.org/10.1136/postgradmedj-2015-133691</mixed-citation><mixed-citation xml:lang="en">Collier A, Stirling A, Cameron L, Hair M, Crosbie D. Gout and diabetes: a common combination. Postgrad Med J. 2016;92(1089):372-378. https://doi.org/10.1136/postgradmedj-2015-133691</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">McAdams-DeMarco MA, Maynard JW, Baer AN, Coresh J. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in communities cohort. J Clin Hypertens (Greenwich). 2012;14(10):675-679. https://doi.org/10.1111/j.1751-7176.2012.00674.x</mixed-citation><mixed-citation xml:lang="en">McAdams-DeMarco MA, Maynard JW, Baer AN, Coresh J. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in communities cohort. J Clin Hypertens (Greenwich). 2012;14(10):675-679. https://doi.org/10.1111/j.1751-7176.2012.00674.x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016;75(8):1473-1478. https://doi.org/10.1136/annrheumdis-2015-208161</mixed-citation><mixed-citation xml:lang="en">Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016;75(8):1473-1478. https://doi.org/10.1136/annrheumdis-2015-208161</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49(4):595-599. https://doi.org/10.1016/j.jhep.2008.05.024</mixed-citation><mixed-citation xml:lang="en">Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49(4):595-599. https://doi.org/10.1016/j.jhep.2008.05.024</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. https://doi.org/10.1016/j.jhep.2019.06.021</mixed-citation><mixed-citation xml:lang="en">Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. https://doi.org/10.1016/j.jhep.2019.06.021</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). J Hypertens. 1998;16(12 Pt 2):2113-2116.</mixed-citation><mixed-citation xml:lang="en">Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). J Hypertens. 1998;16(12 Pt 2):2113-2116.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Блинова Н.В., Аксенова А.В., Подзолков В.И., Тарзиманова А.И., Амбатьелло Л.Г., Чазова И.Е. Применение бета-адреноблокаторов у пациентов с артериальной гипертонией. Системные гипертензии. 2025;22(3):5-18. https://doi.org/10.38109/2075-082X-2025-3-5-18</mixed-citation><mixed-citation xml:lang="en">Blinova N.V., Aksenova A.V., Podzolkov V.I., Tarzimanova A.I., Ambatiello L.G., Chazova I.E. Medical Society of Hypertension. Use of beta-blockers in patients with hypertension. Systemic Hypertension. 2025;22(3):5-18. (In Russ.) https://doi.org/10.38109/2075-082X-2025-3-5-18</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Chen R, Suchard MA, Krumholz HM, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 2021;78(3):591-603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667</mixed-citation><mixed-citation xml:lang="en">Chen R, Suchard MA, Krumholz HM, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 2021;78(3):591-603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammad A., Abujbara M., Alshraideh J., Jaddou H., Ajlouni K. The Prevalence of Resistant Hypertension Among Type 2 Diabetic Patients Attending the National Center for Diabetes, Endocrinology, and Genetics. J Endocrinol Metab. 2017;7(5):153-158. https://doi.org/10.14740/jem448e</mixed-citation><mixed-citation xml:lang="en">Mohammad A., Abujbara M., Alshraideh J., Jaddou H., Ajlouni K. The Prevalence of Resistant Hypertension Among Type 2 Diabetic Patients Attending the National Center for Diabetes, Endocrinology, and Genetics. J Endocrinol Metab. 2017;7(5):153-158. https://doi.org/10.14740/jem448e</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Narkiewicz K, Kjeldsen SE, Egan BM, Kreutz R, Burnier M. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Press. 2022;31(1):207-209. https://doi.org/10.1080/08037051.2022.2107483</mixed-citation><mixed-citation xml:lang="en">Narkiewicz K, Kjeldsen SE, Egan BM, Kreutz R, Burnier M. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Press. 2022;31(1):207-209. https://doi.org/10.1080/08037051.2022.2107483</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Kreutz R, Brunstrom M, et. al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480. Epub 2023 Sep 26. Erratum in: J Hypertens. 2024 Jan 1;42(1):194. PMID: 37345492. https://doi.org/10.1097/HJH.0000000000003621</mixed-citation><mixed-citation xml:lang="en">Mancia G, Kreutz R, Brunstrom M, et. al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480. Epub 2023 Sep Erratum in: J Hypertens. 2024 Jan 1;42(1):194. PMID: 37345492. https://doi.org/10.1097/HJH.0000000000003621</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Grodzinsky A, Kosiborod M, Tang F, et al. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017;10(9):e003553. https://doi.org/10.1161/CIRCOUTCOMES.117.003553</mixed-citation><mixed-citation xml:lang="en">Grodzinsky A, Kosiborod M, Tang F, et al. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017;10(9):e003553. https://doi.org/10.1161/CIRCOUTCOMES.117.003553</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell Metab. 2021;33(8):1519-1545. https://doi.org/10.1016/j.cmet.2021.07.0</mixed-citation><mixed-citation xml:lang="en">Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell Metab. 2021;33(8):1519-1545. https://doi.org/10.1016/j.cmet.2021.07.0</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
